- Home
- VCTR vs MRUS Comparison
VCTR vs MRUS Comparison
Compare VCTR & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCTR
- MRUS
- Stock Information
- Founded
- VCTR 2013
- MRUS 2003
- Country
- VCTR United States
- MRUS Netherlands
- Employees
- VCTR N/A
- MRUS N/A
- Industry
- VCTR Investment Managers
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- VCTR Finance
- MRUS Health Care
- Exchange
- VCTR Nasdaq
- MRUS Nasdaq
- Market Cap
- VCTR 4.8B
- MRUS 4.1B
- IPO Year
- VCTR 2018
- MRUS 2016
- Fundamental
- Price
- VCTR $71.18
- MRUS $67.40
- Analyst Decision
- VCTR Buy
- MRUS Strong Buy
- Analyst Count
- VCTR 10
- MRUS 13
- Target Price
- VCTR $72.30
- MRUS $90.92
- AVG Volume (30 Days)
- VCTR 628.1K
- MRUS 558.3K
- Earning Date
- VCTR 08-07-2025
- MRUS 10-30-2025
- Dividend Yield
- VCTR 2.71%
- MRUS N/A
- EPS Growth
- VCTR 12.49
- MRUS N/A
- EPS
- VCTR 4.00
- MRUS N/A
- Revenue
- VCTR $1,028,813,000.00
- MRUS $56,228,000.00
- Revenue This Year
- VCTR $47.18
- MRUS $57.42
- Revenue Next Year
- VCTR $15.21
- MRUS $0.23
- P/E Ratio
- VCTR $18.07
- MRUS N/A
- Revenue Growth
- VCTR 20.90
- MRUS 59.77
- 52 Week Low
- VCTR $47.00
- MRUS $33.19
- 52 Week High
- VCTR $73.42
- MRUS $69.20
- Technical
- Relative Strength Index (RSI)
- VCTR 53.34
- MRUS 58.24
- Support Level
- VCTR $69.33
- MRUS $62.80
- Resistance Level
- VCTR $72.13
- MRUS $67.84
- Average True Range (ATR)
- VCTR 1.31
- MRUS 2.36
- MACD
- VCTR -0.15
- MRUS -0.23
- Stochastic Oscillator
- VCTR 56.30
- MRUS 70.78
About VCTR Victory Capital Holdings Inc.
Victory Capital Holdings Inc is an independent investment management firm. The company operates its business through franchises and solutions platform. It provides centralized distribution, marketing, and operations infrastructure to the company's franchises and solutions platform. The company operates through one business segment that is Investment management services and products to institutional, intermediary, retirement platforms, and individual investors. The franchises and solutions platform manages a variety of investment strategies for its customers. It derives majority of its revenues from asset-based fees from investment management products and services to individuals and institutions.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.